Introduction
Radiotherapy is one of the most common and effective treatments for cancer (1) . Over 40% of patients with cancer require radiotherapy during the management of the disease (2) . Although clinical radiotherapy treatment planning and delivery technologies have improved, the toxicity of radiotherapy to non-cancerous tissues and organs remains a problem (2, 3) . Thus, radioprotective compounds are crucial in clinical radiotherapy (3) , and the administration of radioprotective compounds has been suggested as an approach for preventing radiation-damage in normal tissues (4, 5) .
Selenium is a trace element with a fundamental role in human biology (6) . It detoxifies reactive oxygen species (ROS) produced by radiation treatment (4, 7) . In human antioxidant systems, selenium acts in the form of selenocysteine, which is incorporated into various selenoproteins (8, 9) . At least 25 selenoproteins have been identified in humans, including glutathione peroxidase (GPx), thioredoxin reductases, iodothyronine deiodinase and the selenoproteins P, W and R (10) . Selenium exists in numerous chemical forms, of which the most studied are selenomethionine, sodium selenite, methylselenocysteine, 1,4-phenylenebis (methylene) selenocyanate and methylseleninic acid (9) . Sodium selenite is the chemical form of selenium previously used in clinical studies of radiotherapy supplementation between 1987 and 2012 (7) . Despite having been previously used as a complementary medicine during clinical radiotherapy (11, 12) , the effectiveness of selenium use in radiotherapy and the mechanisms underlying the effect of selenium in reducing the side effects of radiotherapy require further study (7) . Schleicher et al (13) and Rodemann et al (14) performed in vitro studies of selenium and radiotherapy and identified that sodium selenite has potential as a protective agent for non-cancerous tissues during radiotherapy (15) . However, the mechanisms underlying this protection have yet to be revealed. Diamond et al (16) demonstrated that low-level supplementation of culture media with sodium selenite significantly protected CHO-AA8 cells, a hamster ovary-derived cell line, from radiation-induced mutagenesis. Eckers et al (17) also reported that the overexpression of selenoprotein P suppressed radiation-induced ROS accumulation and protected normal human fibroblasts from radiation-induced toxicity. Tak et al (18) identified that, when U937 human leukemic monocyte lymphoma cells were exposed to 2 Gy of γ-radiation, a marked difference with respect to apoptotic features and mitochondrial function was observed between the cells that were and were not pre-treated with ebselen.
Further studies are required in order to determine the mechanisms underlying selenium-induced prevention of radiotherapy side effects, before it may be recommended as an adjuvant to cancer radiotherapy. Sodium selenite is the only chemical form of selenium that has previously been used in clinical studies for this purpose; therefore, the present study investigated the protective effects of sodium selenite supplementation on non-cancerous human esophageal cells, a cell type with high radiosensitivity, prior to X-ray irradiation.
Materials and methods
Cell culture. The CHEK-1 immortalized non-cancerous human esophageal cell line was provided by Dr H. Matsubara (Department of Academic Surgery, Chiba University, Japan) (19) and maintained in RPMI-1640 medium (Wako Pure Chemical Industries, Ltd., Osaka, Japan) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Waltham, MA, USA), and incubated at 37˚C in a humidified chamber containing 5% CO 2 . The culture medium was replaced every 3 days and the cells were passaged on a weekly basis using a 1:5 splitting ratio.
Selenium supplementation. Sodium selenite (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) was the chemical form of selenium that was used for supplementation of the cell medium. The sodium selenite supplementation doses ranged from 0-200 nM, and the duration of incubation was 24-72 h, 18 h following initial cell seeding at a density of 1x10 6 cells in a 10 ml/10 cm culture dish or 2x10 3 cells/50 µl well. Supplementation with a dose of 50 nM sodium selenite for 72 h prior to radiation treatment was used for the cell viability assay, cell cycle analysis and western blot analysis.
Irradiation. Irradiation was performed using an X-Ray irradiation machine (Titan-225S; Shimadzu Corporation, Kyoto, Japan) at a rate of 1.3 Gy/min. The dose of irradiation was 2 Gy based on the common fractionation dose for radiotherapy.
Protein extraction for GPx-1 activity assay and western blot analysis. CHEK-1 cells were supplemented with 50 nM sodium selenite for 72 h, washed twice with PBS and harvested by adding a solution of 1 mM EDTA in PBS, then removing the cells from the culture dish using a cell scraper. Proteins were then extracted using a radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck Millipore) with a 10% protein inhibitor cocktail (Sigma-Aldrich; Merck Millipore). The protein concentrations were determined using a DC™ protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) following the method of Lowry et al (20) . The extracted samples were stored at -80˚C until the time of analysis.
GPx-1 activity assay. The enzymatic activity of GPx-1 in CHEK-1 cell homogenates was determined using the method described by Paglia and Valentine (21), with certain modifications. Briefly, GPx-1 activity was indirectly monitored using spectrophotometric methods to observe the reduction of oxidized glutathione, using nicotinamide adenine dinucleotide phosphate (NADPH) as the reducing agent. GPx-1 activity was quantified by measuring the change in NADPH absorbance at 340 nm and was expressed as the change in NADPH absorbance (Δ mM NADPH) over time (min) and with various levels of protein (mg) in the presence of the substrate tert-butyl hydroperoxide. The absorbance was recorded using a SpectraMax Plus 384 microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).
Cytotoxicity assay. The cytotoxicity of sodium selenite in CHEK-1 cells was examined with various concentrations of sodium selenite (0-8 µM) using a colorimetric assay. Briefly, cells (2x10 3 in 50 µl/well) were seeded into 96-well plates. Sodium selenite solutions were added 18 h following the initial cell seeding, and the cells were then incubated for 72 h at 37˚C in a humidified chamber containing 5% CO 2. The cell proliferation rate and half-maximal inhibitory concentration (IC 50 ) were then determined using a Cell Counting kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer's protocol. The absorbance was measured at a wavelength of 450 nm using a SpectraMax Plus 384 microplate reader. The data was analyzed using linear regression analysis.
Clonogenic assay. The survival of the cells post-irradiation was investigated by conducting clonogenic and cell viability assays. To conduct the clonogenic assay, the CHEK-1 cell media was supplemented with various concentrations of sodium selenite (0-200 nM) for 72 h from 18 h following the initial seeding, and were then irradiated with 2 Gy X-ray radiation. Immediately following irradiation, the cells (500 cells/4 ml medium) were seeded in Falcon 25 cm 2 tissue culture flasks. Following 14 days of culture at 37˚C, the cells were washed once with PBS, fixed with 99.5% ethanol and stained with 0.5% crystal violet in H 2 O:methanol (1:1) for 30 min at room temperature. The cells were then washed with tap water and air-dried. The total number of colonies containing >50 cells were counted using a binocular light microscope (Olympus Corporation, Tokyo, Japan). Following the counting of the colonies, the plating efficiency (PE) and survival fraction (SF) were calculated using the following equations (22, 23) .
Cell viability assay. To observe cell viability post-irradiation, CHEK-1 cells (2x10 3 in 50 µl/well) were seeded in 96-well plates. Sodium selenite (50 nM) solution was added at 18 h following initial cell seeding, and the cells were incubated for 72 h prior to irradiation. Post-irradiation cell viability was examined every hour for 72 h using a Cell Counting kit-8, according to the manufacturer's protocol. The absorbance was measured at a wavelength of 450 nm using a SpectraMax Plus 384 microplate reader.
Cell cycle analysis. Detached and attached cells were collected at the end of each post-irradiation time point (24, 48 and 72 h). Detached cells were collected from the medium. Attached cells were collected by adding a TrypLE™ Express solution (Thermo Fisher Scientific, Inc.) to attached cells and incubating at 37˚C in a humidified chamber containing 5% CO 2 until the cells had detached. Detached and attached suspension cells were centrifuged at 168 x g for 4 min at room temperature, the supernatant was removed and cells were washed twice with ice-cold PBS. The cells were fixed with 70% cold ethanol and stored at -20˚C until the time of analysis (1-4 days) . On the day of analysis, the cells were washed with PBS, stained with 0.05 mg/ml of propidium iodide solution (Sigma-Aldrich, St. Louis, MO, USA) with 0.002 mg/ml RNAse (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and incubated at room temperature for 30 min. The DNA content was analyzed using fluorescence-activated cell sorting (FACSCalibur™; BD Biosciences, San Jose, CA, USA).
Western blot analysis. Total proteins were extracted from the cells and measured following sodium selenite supplementation at 72 h post-irradiation. Protein (30 µg) samples were subjected to electrophoresis on a 5-20% SuperSep™ Ace Ready Gel (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and electrotransferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Chalfont, UK). Prior to antibody treatment, the membrane was blocked with 5% w/v non-fat dry milk in a solution of 1X Tris-buffered saline and 0.1% polysorbate 20 by agitating for 45 min at room temperature. The protein levels were analyzed by incubating with (ADP ribose) polymerase (PARP) polyclonal antibody (Cell Signaling Technology, Inc., Danvers, MA, USA; cat. no. 9542; dilution 1:1,000) at 4˚C, overnight. A horseradish peroxidase-conjugated donkey anti-rabbit IgG secondary antibody (GE Healthcare Life Sciences; cat. no. NA934; dilution 1:10,000) was used by incubating with gentle agitation for 90 min at room temperature. Protein bands were detected using an enhanced chemiluminescence detection system (GE Healthcare Life Sciences). A mouse anti-GAPDH antibody (cat. no. MAB374; Abcam, Cambridge, UK; dilution 1:500) served as the loading control. Scanning densitometry was performed using Image Quant LAS 4000 (Amersham, Buckinghamshire, UK) and the autoradiographs were quantified using ImageJ software version 1.50a (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. The data were presented as the mean ± standard error from three independent experiments. The differences between multiple variables were analyzed by one-way analysis of variance and the Bonferroni pairwise comparison was used for post-hoc analysis. All statistical analyses were performed using the EZR (Easy R) statistical software program, an open-source statistical software program which is based on R and R commander version 2.5.5 (24). P<0.05 was considered to indicate a statistically significant difference.
Results
Sodium selenite increases GPx-1 activity. In CHEK-1 cells, sodium selenite supplementation was observed to increase GPx-1 activity in a dose-and time-dependent manner (Fig. 1) . A previous study reported that 50 nM sodium selenite was used as a supplementation dose in primary keratinocytes prior to UV radiation treatment (25) . In the present study, when 50 nM sodium selenite solution was administered to CHEK-1 cells with a 72 h incubation time, maximal GPx-1 activity was achieved. By examining various concentrations of sodium selenite with the same 72 h incubation time, GPx-1 activity was observed to become saturated at a concentration of 50 nM. Therefore, the sodium selenite dose that induced the highest GPx-1 activity was 50 nM for 72 h; these conditions were subsequently used for further experiments.
Cytotoxicity of sodium selenite in CHEK-1 cells. Fig. 2 depicts the cytotoxicity of sodium selenite in CHEK-1 cells based on the percentage of cell proliferation inhibition. The IC 50 was determined to be 3.6 µM. The dose of 50 nM sodium selenite was assumed to be a low and safe dose for supplementation for the cells, compared with the IC 50 dose (3.6 µM). In addition, using linear regression analysis, 50 nM sodium selenite supplementation was estimated to inhibit ≤3% of cell proliferation.
Sodium selenite supplementation increases the post-irradiation cell survival rate. Post-irradiation survival of CHEK-1 cells was observed using a clonogenic assay and cell viability assay. Fig. 3A presents the colony formation of the cells at 14 days post-irradiation. Sodium selenite supplementation increased post-irradiation cell survival by increasing the percentage of surviving cells in a dose-dependent manner, though this trend was not statistically significant. Fig. 3B depicts cell viability at 24-72 h post-irradiation; at 72 h post-irradiation, the viability of the cells treated with 50 nM sodium selenite and 2 Gy irradiation was increased, compared with 2 Gy irradiation alone (P=0.031). These results suggested that sodium selenite supplementation prior to irradiation protects the cells from irradiation-induced damage.
Sodium selenite supplementation reduces the proportion of sub-G1 phase cells post-irradiation.
The cell cycle distribution of CHEK-1 cells post-irradiation is presented in Fig. 4 . The percentages of cells observed to be in sub-G 1 , G 1 , G 2 /M and S phases at 72 h in the untreated control groups were 2.7±0.03, 71.2±5.01, 22.5±1.03 and 3.5±4.44%, respectively, whereas these percentages for cells in the 50 nM sodium selenite groups were 2.5±0.11, 64.6±3.21, 24.3±0.94 and 8.6±2.85, respectively. These results indicate that the cell cycle profile was not affected by treatment with sodium selenite, with the exception of a non-significant decrease in the number of G 1 cells from 71.2 to 64.6% (P=1.00) between the control and sodium selenite groups. Treatment with 2 Gy X-ray radiation increased the percentage of sub-G 1 phase cells from 2.8 to 5.9% (P=0.00087) and non-significantly decreased the percentage of G 1 phase cells from 71.2 to 58.8% at 72 h post-irradiation (P=0.33). Combined treatment with 50 nM sodium selenite and 2 Gy X-ray irradiation resulted in a reduced percentage of sub-G 1 cells (4.2 vs. 5.9%; P= 0.0061) and a non-significant increase in the percentage of G 1 cells (62.1 vs. 58.8%; P=1.00) at 72 h post-irradiation, compared with 2 Gy X-ray irradiation alone. These results indicate that sodium selenite supplementation prior to irradiation may reduce the percentage of apoptotic and damaged cells, and promote entry into the G 1 phase following irradiation.
Protein expression levels of PARP, an apoptosis biomarker.
The expression levels of PARP protein, a principal biomarker for apoptosis, were analyzed by western blotting 72 h post-irradiation. The expression levels of PARP and cleaved PARP proteins are depicted in Fig. 5 . GAPDH protein was used as a loading control. Treatment of the CHEK-1 cells with 2 Gy X-ray radiation increased the expression levels of cleaved PARP post-irradiation (P=0.0394). Additionally, combination treatment with 50 nM sodium selenite and 2 Gy X-ray irradiation reduced the expression levels of cleaved PARP, as compared with irradiation alone; however, this difference was not statistically significant (P= 0.423). These results indicate that sodium selenite may potentially inhibit radiation-induced apoptosis in non-cancerous cells. 
Discussion
The present study demonstrated that the supplementation of non-cancerous human esophageal cells with 50 nM sodium selenite prior to radiotherapy may protect the cells from radiation-induced damage and that this protection may be due to the inhibition of radiation-induced apoptosis. These results are concordant with those of a previous study that used the organoselenium compound ebselen for the supplementation of U937 cells prior to irradiation treatment (18) .
Irradiation kills not only tumor cells but also proliferating normal cells (2) . Additionally, irradiation stimulates the production of ROS, which induce apoptotic cell death (26) . One method of radioprotection involves the inhibition of caspase activation and PARP cleavage (2) . PARP cleavage is often associated with apoptosis and caspase activation (27) . By reducing the expression levels of cleaved PARP, which is potentially a molecular target for novel radioprotective compounds, sodium selenite supplementation may serve as a radioprotective compound for normal cells when administered prior to clinical radiotherapy.
GPx is an important enzyme of the cellular antioxidant defense systems that detoxify peroxides and hydroperoxides. Selenocysteine is present at the catalytic site of GPx and the availability of selenium regulates GPx enzyme activity (28) . The stimulation of GPx activity following selenium supplementation indicates that the antioxidant function of this enzyme directly reduces the oxidative DNA damage associated with radiation exposure (16) . The current study demonstrated that sodium selenite supplementation increases GPx-1 activity, which is concordant with a previous study by Diamond et al (16) , indicating that the low-level supplementation of culture media with selenium, in the form of sodium selenite, markedly protected CHO-AA8 Chinese hamster ovary-derived cells from radiation-induced mutagenesis and that this protection was associated with a significant elevation in GPx-1 activity.
In conclusion, the present study investigated the protective effects of sodium selenite supplementation against irradiation-induced damage in non-cancerous esophageal cells. The results suggest that treatment with 50 nM sodium selenite supplementation for 72 h prior to irradiation protects normal cells from irradiation-induced damage by inhibiting irradiation-induced apoptosis; therefore, sodium selenite may be a potential radioprotective compound for use in clinical radiotherapy. Husbeck et al (29) previously reported that alteration of the redox environment of prostate cancer cells by sodium selenite supplementation increased their apoptotic potential and sensitized them to radiation-induced cell death. However, further studies are required to fully elucidate the effects of sodium selenite supplementation on esophageal cancer cells.
